Toll like receptor 2

Where the papers sit

10 papers from the last 6 months study toll like receptor 2 directly · updated from PubMed 24 Oct 2026

• Antibody-Based TLR2 Modulation

  Antibody engineering is being used to block or reshape TLR2-driven inflammation in pain and infection. Structure-guided scFv work localizes recognition to complementarity-determining regions, while recombinant anti-TLR2 antibodies are paired with PLGA gene delivery for neuropathic pain. CLEC5A/TLR2 bispecific blockade suppresses dengue-induced macrophage cytokines. The shared aim is selective control of cytokine production, although vaccine design broadens the application beyond direct TLR2 inhibition.

  4 papers · 40%

• Small-Molecule TLR2 Antagonists

  Structure-based screening is driving the search for small-molecule TLR2 antagonists rather than nonspecific inflammatory suppression. Molecular dynamics, chemical profiling and network pharmacology are used to prioritize binding candidates and multitarget mechanisms. 3-fluoro-2-hydroxybenzaldehyde derivatives are being synthesized and tested in HEK-Blue hTLR2 assays. The main open question is whether computationally predicted binding translates into selective, biologically durable antagonism.

  3 papers · 30%

• Microbial TLR2 Signaling

  Microbial ligands are being linked to TLR2 control of NF-κB and downstream inflammatory responses across infection, systemic disease and cancer therapy. Curli fibers and Mycoplasma pneumoniae illustrate distinct routes for protein- and receptor-level tuning, including Neu1 sialidase and the Siglec-5/Siglec-14 pair. Microbial levan is instead being used to potentiate a hepatic PEGylated benzimidazole-curcumin nanocomplex through TLR2-FXR/FGF1 signaling. The common theme is context-dependent coupling of innate sensing to inflammation or antitumor activity, with no single intervention yet dominant.

  3 papers · 30%